Next Article in Journal
Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY)
Next Article in Special Issue
The Role of circRNAs in Human Papillomavirus (HPV)-Associated Cancers
Previous Article in Journal
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
Previous Article in Special Issue
circ2GO: A Database Linking Circular RNAs to Gene Function
Open AccessArticle

Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy

1
Biochemistry Center Regensburg (BCR), Laboratory for RNA Biology, University of Regensburg, 93053 Regensburg, Germany
2
Laboratory for Systems Biology of Gene Regulatory Elements, Berlin Institute for Medical Systems Biology, Max-Delbruck Center for Molecular Medicine, 10115 Berlin, Germany
3
Biozentrum, University of Basel, 4056 Basel, Switzerland
4
Department of Surgery, University Hospital Regensburg, 93053 Regensburg, Germany
*
Authors to whom correspondence should be addressed.
Cancers 2021, 13(1), 49; https://doi.org/10.3390/cancers13010049
Received: 28 November 2020 / Revised: 21 December 2020 / Accepted: 23 December 2020 / Published: 26 December 2020
(This article belongs to the Special Issue Circular RNAs in Cancer)
Colorectal cancer is one of the most frequent types of cancer world-wide, leading to over 500,000 cancer-related deaths each year. Although many primary colorectal cancer patients can be cured by surgery, up to 60% will develop metastases. Chemotherapeutic strategies are well-established, but finally often lead to chemo-resistance and tumor relapse. A specific chemotherapeutic approach is low dose metronomic (LDM) therapy, which is based on a constant administration of low doses of a chemotherapeutic compound instead of high-dose pulses, which are often a huge burden for patients and also may induce rapid resistance. However, the molecular mechanism of LDM chemotherapy is not fully understood. Our study therefore aims at identifying gene signatures of colorectal cancer progression under LDM chemotherapy which eventually provides new potential biomarkers for therapeutic interventions.
Understanding the molecular signatures of colorectal cancer progression under chemotherapeutic treatment will be crucial for the success of future therapy improvements. Here, we used a xenograft-based mouse model to investigate, how whole transcriptome signatures change during metastatic colorectal cancer progression and how such signatures are affected by LDM chemotherapy using RNA sequencing. We characterized mRNAs as well as non-coding RNAs such as microRNAs, long non-coding RNAs and circular RNAs in colorectal-cancer bearing mice with or without LDM chemotherapy. Furthermore, we found that circZNF609 functions as oncogene, since over-expression studies lead to an increased tumor growth while specific knock down results in smaller tumors. Our data represent novel insights into the relevance of non-coding and circRNAs in colorectal cancer and provide a comprehensive resource of gene expression changes in primary tumors and metastases. In addition, we present candidate genes that could be important modulators for successful LDM chemotherapy. View Full-Text
Keywords: LDM topotecan chemotherapy; miRNA; interferon-induced genes; lncRNAs; LINC00483; MIR210HG; micropeptide; circRNA; circZNF609; colorectal cancer LDM topotecan chemotherapy; miRNA; interferon-induced genes; lncRNAs; LINC00483; MIR210HG; micropeptide; circRNA; circZNF609; colorectal cancer
Show Figures

Graphical abstract

MDPI and ACS Style

Ho-Xuan, H.; Lehmann, G.; Glazar, P.; Gypas, F.; Eichner, N.; Heizler, K.; Schlitt, H.J.; Zavolan, M.; Rajewsky, N.; Meister, G.; Hackl, C. Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. Cancers 2021, 13, 49. https://doi.org/10.3390/cancers13010049

AMA Style

Ho-Xuan H, Lehmann G, Glazar P, Gypas F, Eichner N, Heizler K, Schlitt HJ, Zavolan M, Rajewsky N, Meister G, Hackl C. Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. Cancers. 2021; 13(1):49. https://doi.org/10.3390/cancers13010049

Chicago/Turabian Style

Ho-Xuan, Hung; Lehmann, Gerhard; Glazar, Petar; Gypas, Foivos; Eichner, Norbert; Heizler, Kevin; Schlitt, Hans J.; Zavolan, Mihaela; Rajewsky, Nikolaus; Meister, Gunter; Hackl, Christina. 2021. "Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy" Cancers 13, no. 1: 49. https://doi.org/10.3390/cancers13010049

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop